Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2013

Oxnard Geoffrey R, Jänne Pasi A

Abstract excerpt

Widespread tumor genotyping has increased the complexity of lung cancer care, often identifying mutations of uncertain clinical significance. In the accompanying article, the authors carried out a meta-analysis of the published literature on EGF receptor (EGFR) genotype and erlotinib/gefitinib se...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to EGF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 23403632
DOI: 10.1158/1078-0432.CCR-13-0169
PMCID: PMC4327821

Genes

EGF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23403632-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes.PMID 23403632Read ↗

Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma.Semantic proximity Read ↗

Mutations in the EGFR: the importance of genotyping.Semantic proximity Read ↗

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Semantic proximity Read ↗

Quantitative <i>in vivo</i> analyses reveal a complex pharmacogenomic landscape in lung adenocarcinomaSemantic proximity Read ↗

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.Semantic proximity Read ↗

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.Semantic proximity Read ↗

Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.Semantic proximity Read ↗

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.Semantic proximity Read ↗

Atypical EGFR Mutations Show Heterogeneity.Semantic proximity Read ↗

Role of genotyping in non-small cell lung cancer treatment: current status.Semantic proximity Read ↗

Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In VivoSemantic proximity Read ↗

Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.